** Shares of medical device maker Dexcom DXCM.O fall 6.2% to $73 in extended trade
** Co says it had received a warning letter from the U.S. FDA following inspections of its two key manufacturing facilities
** The warning letter contains observations and identified issues in manufacturing processes and quality management system at DXCM's facilities in San Diego, California and Mesa, Arizona
** Co does not expect a material impact from the letter to its manufacturing capacity or its sales outlook for fiscal year 2025
** DXCM fell 37.3% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。